Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

NCT03319316 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Interest withdrawn

Conditions

Squamous Non-small Cell Lung Cancer
Non-Squamous Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC